Proposed Proarrhythmic Cardiac Safety Education in Medical,Pharmacy,and Nursing Schools

Link MG Yan G-X Kowey PR . Evaluation of toxicity for heart failure therapeutics: studying effects on the QT interval. Circ Heart Fail. 2010;3:547–555.

Turner JR Karnad DR Kothari S . Cardiovascular Safety in Drug Development and Therapeutic Use: New Methodologies and Evolving Regulatory Landscapes. Gewerbestrasse, Switzerland: Springer International Publishing; 2017.

Vandetanib Prescribing Information. http://www.caprelsa.com/. Accessed August 7, 2018.

Turner JR. Cardiac safety education: A Call to Action. AMPS-QT, 3rd Quarter 2017 issue. http://www.amps-llc.com/uploads/2017-12-7/AMPS-QT_3q17.pdf. Accessed August 7, 2018.

Turner JR . Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use. Expert Opin Drug Saf. 2017;16:481–492.

Turner JR Rodriquez I Mantovani E , et al; on behalf of the Cardiac Safety Research Consortium. Drug-induced proarrhythmia and torsade de pointes: a primer for students and practitioners of medicine and pharmacy. J Clinical Pharmacol. 2018;58:997–1012.

Vlachos K Georgopoulos S Efremidis M Sideris A Letsas KP . An update on risk factors for drug-induced arrhythmias. Expert Rev Clin Pharmacol. 2016;9:117–127.

Vandael E Vandenberk B Vandenberg J Willems R Foulon V . Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39:16–25.

Heemskerk CPM Pereboom M van Stralen K . Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018;74:183–191.

Beach SR Celano CM Sugrue AM . QT Prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics. 2018;59:105–122.

Dhanani TC Mantovani EH Turner JR . Clinical pharmacists’ opportunities to reduce inappropriate prescription of QT-prolonging medications: calls to action. Int J Pharm Pract. 2017;25:176–179.